Detalles de la búsqueda
1.
Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings.
J Clin Rheumatol
; 27(8): e446-e455, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32826654
2.
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.
Clin Exp Rheumatol
; 37(2): 260-269, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30148436
3.
Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis.
Rheumatol Int
; 38(11): 2121-2131, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30094685
4.
Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study.
RMD Open
; 6(2)2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32611650
5.
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Semin Arthritis Rheum
; 50(4): 709-718, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32521325
6.
Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
J Med Econ
; 22(1): 45-52, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30346844
7.
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.
Eur J Rheumatol
; 6(3): 113-121, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364979
8.
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.
Clinicoecon Outcomes Res
; 10: 477-491, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30214261
9.
Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
J Med Econ
; 21(2): 163-173, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28945143
10.
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
J Comp Eff Res
; 7(11): 1107-1123, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30230361
11.
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.
Eur J Rheumatol
; 5(4): 216-223, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30388073
12.
Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
Arthritis Care Res (Hoboken)
; 70(10): 1529-1535, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409133
13.
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
Arthritis Res Ther
; 20(1): 113, 2018 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880010
14.
Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
Rheumatol Ther
; 5(2): 595, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29858770
15.
Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
Rheumatol Ther
; 5(1): 99-122, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29605841
Resultados
1 -
15
de 15
1
Próxima >
>>